Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2019 · 10-Q
Revenue$581.00K$581.00K+109.0% vs Q2 2018 Net Income$219.00K$219.00KN/M vs Q2 2018 EPS Diluted$0.00$0.00N/M vs Q2 2018 Operating Income-$6,637,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1142.3%+6179.2 pt vs Q2 2018
Net margin37.7%+7655.3 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end